权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Evaluating an Intervention to Improve Medication Access and Quality of Care for Underserved Populations With Chronic Conditions

评估改善服务不足的慢性病人群的药物获取和护理质量的干预措施

基本信息

批准号：
10708868
负责人：
Anna D Sinaiko
金额：
$ 60.35万
依托单位：
HARVARD SCHOOL OF PUBLIC HEALTH
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-22 至 2026-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10708868
关键词：
Address Affect Ambulatory Care Area Asthma Atrial Fibrillation Attitude Behavior Belief Black Populations Black race COVID-19 pandemic Caring Characteristics Chronic Chronic Disease Clinical Colorado Data Data Set Diabetes Mellitus Discrimination Disease Disparity population Electronic Health Record Ethnic Origin Focus Groups Frequencies Goals Guidelines Health Health Status Health system Healthcare Systems Hispanic Hispanic Populations Household Improve Access Income Intervention Interview Language Latino Latino Population Learning Link Marketing Measures Medical Medicare Mental Depression Morbidity - disease rate Outcome Patient Preferences Patient-Focused Outcomes Patients Pharmaceutical Preparations Pharmacy facility Policies Population Provider Quality of Care Race Registries Research Residencies Resources Rural Rural Population Sampling Site Structural Racism System Telemedicine Time Travel Trust Underserved Population Universities Variant acute care care episode clinical encounter cost cost estimate data registry data tools demographics design disparity reduction ethnic minority evidence base evidence based guidelines experience health disparity health literacy implementation strategy implementation tool improved longitudinal dataset mortality novel patient population poor health outcome practice factors preference racial minority rural area rural patients rural residence tool treatment choice treatment services

项目摘要

Underuse of evidence-based medications for chronic disease, driven in part by high out-of-pocket (OOP) medication costs, accounts for substantial preventable morbidity and mortality due to exacerbation of chronic illnesses. This underuse, and the resultant adverse health outcomes, are worse for patients who are Black, Hispanic, or Latino, and those who live in rural areas. Addressing gaps in cost information may reduce OOP spending and improve underuse. Sometimes clinicians prescribe more expensive agents when less costly, equally effective medications exist, in part because, until recently, they lacked information regarding what patients must pay for a particular drug. OOP cost information could also help patients and clinicians make treatment choices that are consistent with patient preferences and goals. In 2019, the University of Colorado Health System (UCHealth) implemented in all ambulatory care sites a Real-Time Benefit Tool (RTBT) that shows clinicians a patient’s OOP medication costs—the cost the patient would pay at a pharmacy—in the Electronic Health Record. Medicare policy supports RTBTs and will increase its implementation. Because cost- related medication underuse is significant among racial/ethnic minority and rural populations, a RTBT has the potential to increase guideline-concordant care in these populations and decrease disparities. On the other hand, use of RTBT may be less frequent among populations with chronic conditions who are Black, Hispanic, Latino, or in rural areas due to differences in where care is received (e.g. telemedicine), health literacy and language, cultural identity and norms, medical system behaviors that erode trust, or interpersonal and structural racism within the health care system. The project will focus on patients with asthma, atrial fibrillation, diabetes, or depression—common chronic conditions for which there are both costly and low-cost clinically effective drugs—and measure (1) outcomes among patients who are Black, Hispanic, or Latino, or who live in rural areas and (2) how these outcomes differ compared with other patients with the same chronic conditions. We will use unique UCHealth data linking clinical medication orders, pharmacy claims, patient data (including race, ethnicity, other demographics, and health status), and RTBT data to assess variation in RTBT use and whether the RTBT is associated with patients’ first medication fills. We will use the Colorado All-Payer Claims data and a difference-in-difference design to measure the impact of the RTBT on use of medications consistent with national evidence-based recommendations and on poor health outcomes. We will characterize via interviews and focus groups whether and how RTBT affects experiences, is consistent with patient preferences in their clinical encounters, and the factors associated with positive and negative experiences. This project will produce evidence on the policy impact of an RTBT on access and quality of care for Black, Hispanic, Latino, and rural patients with chronic conditions and on health disparities, and on implementation strategies to maximize impact.

慢性疾病的循证药物使用不足，部分原因是高昂的自付费用（OOP）

项目成果

期刊论文数量（1）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Clinician Response to Patient Medication Prices Displayed in the Electronic Health Record.

临床医生对电子健康记录中显示的患者药品价格的回应。

DOI：
10.1001/jamainternmed.2023.3307
发表时间：
2023
期刊：
JAMA internal medicine
影响因子：
39
作者：
Sinaiko,AnnaD;Sloan,CarolineE;Soto,MarkJ;Zhao,Olivia;Lin,Chen-Tan;Goss,FosterR
通讯作者：
Goss,FosterR